Personalized therapeutic cancer vaccine for glioblastoma to help survival
Official title: Personalized Therapeutic Cancer Vaccine for Glioblastoma to Enhance Overall Survival and Prevent Recurrence
Funded at Ne1 INC. · NIH-11253187 · Data updated 2026-11-12
A new, patient-focused vaccine approach uses a patient's own tumor cells to help the immune system recognize and fight glioblastoma, with the goal of longer survival and fewer recurrences.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ne1 INC. NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 8, 2026 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $388,656 |
| NIH project number | 1R43CA306479-01 |
| Project ID | NIH-11253187 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with newly diagnosed glioblastoma who are eligible for standard-of-care treatment and may participate in autologous vaccine development.
✕Less likely to help
Patients with GBM who cannot receive vaccines or who have contraindications to the vaccine components may not benefit.
What this research studies
This project aims to create MBRP-Vax, an autologous tumor cell–based vaccine trained to boost the patient’s own immune response against glioblastoma. It uses nanoparticle-like modifications to make tumor cells more visible to immune cells, hoping to strengthen both innate and adaptive immunity. The study is designed as an SBIR effort to develop this therapy for newly diagnosed GBM patients, focusing on feasibility, safety, and initial hints of benefit. If successful, it could provide a personalized treatment option alongside standard care to delay recurrence and extend life.
Why it matters
Potential benefit: If successful, patients could experience longer overall survival and a lower chance of tumor recurrence.
How similar studies have gone: Autologous tumor vaccines have shown immunogenic activity in early studies, but this approach is still investigational and early in development.
Where this research is happening
-
Ne1 INC.
New York, United States Active
Researchers
- Principal investigator: Chakraborty, Samik — Ne1 INC.
- Study coordinator: Chakraborty, Samik
Related research
Other NIH-funded projects on the same topics.
-
Quantitative imaging tool to tell tumor recurrence from radiation effects in glioblastoma
A non-invasive MRI-based classifier helps doctors distinguish recurrent glioblastoma from treatment-related changes to spare patients unnecessary biopsy.
-
Cell-level look at glioblastoma edges and tumors that come back
This project uses fresh tumor slices and single-cell methods to find which cell types at the tumor core and edge respond to different drugs for people with glioblastoma.
-
How radiation affects brain cells and glioblastoma recurrence
This study looks at how radiation therapy affects the brain and might help glioblastoma, a tough type of brain cancer, come back after treatment, with the hope that what we learn can lead to better ways to fight this disease.
-
Better telling apart tumor growth from treatment effects in Glioblastoma
This project aims to create a new way to tell if changes on an MRI scan for Glioblastoma patients are new tumor growth or harmless side effects from radiation treatment.
-
Keloid recurrence study using multi-omics in diverse patients
A research effort will look at why keloids come back after surgery, especially in African American patients, using comprehensive molecular data from patient samples.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.